Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026.

Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported several transactions in these roles, including Bruker Corporation’s majority-ownership investment in Biognosys AG in 2023, and Chiesi Farmaceutici’s acquisition of Amryt Pharma later the same year.
‍
Dr. Vink previously served as Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, Inc., overseeing global commercial and technical operations until its $9.5 billion acquisition by Merck in 2015. Prior to Cubist, he was Senior Vice President, Global Head of Hospital Business and Biologics for Mylan Inc. (now Viatris Inc.). Earlier in his career, he held senior roles at Novartis Sandoz, Biogen, and Sanofi-Synthelabo. He served as a director of Arch Biopartners from December 2016 until December 2019, and continued to support the Company as a Strategic Advisor thereafter.

“We are happy to have Patrick rejoin the board as our new Chairman during this exciting stage of development for Arch. Patrick’s experience in the pharma industry, combined with his network within the financial markets, will be very helpful to Arch as we advance our acute kidney injury Phase II trials and our chronic kidney disease program,” said Richard Muruvé, CEO of Arch Biopartners.

Dr. Vink’s appointment follows the retirement of Claude Allary from the Board of Directors. Mr. Allary has served as a director since 2014 and helped support Arch evolve into becoming a leading kidney therapeutics company, with two lead drug candidates currently in Phase II trials.

“Claude brought increased credibility, integrity, and wisdom to the Arch board. He served as a director with selfless dedication and with passion, as we developed new drugs to prevent and treat kidney injury. We will miss Claude and wish him a joyful and healthy retirement,” said Mr. Muruvé.

About Arch Biopartners

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch’s development pipeline includes:

• LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI
• Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI
• CKD Platform: next-generation therapeutics targeting chronic kidney disease

These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide. Both lead programs are currently enrolling patients at North American clinical sites.

For more details about the Company’s science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science

Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news.

The Company has 66,933,289 common shares outstanding.

For more information, please contact:

Aaron Benson
Director of Communications
Arch Biopartners Inc.
647-428-7031

Subscribe for trial updates and company news at www.archbiopartners.com/contact-us

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management discussion and analysis under the heading “Business Risks and Uncertainties”. As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company’s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR”) website at www.sedarplus.ca.

The scientific and medical content of this release has been reviewed and approved by the Company’s Chief Science Officer.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.